1 Impact of Adverse Drug Reactions in the outcomes of Tuberculosis

2 Treatment

- 3 Short Title: Drug reactions in anti-TB therapy
- 4 Flávia M. Sant'Anna^{1,2#}, Mariana Araújo-Pereira^{3,4,5#}, Carolina A. S. Schmaltz^{2#}, María B.
- 5 Arriaga^{3,4,5#}, Bruno B. Andrade^{3,4,5,6,7*}, Valeria C. Rolla^{1,2*}
- 6
- 7 ¹Postgraduate Program Clinical Research in Infectious Diseases, National Institute of Infectious
- 8 Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
- 9 ²Clinical Research Laboratory on Mycobacteria, (LAPCLIN-TB), National Institute of Infectious
- 10 Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
- ¹¹ ³School of Medicine, Federal University of Bahia, Salvador, Brazil
- 12 ⁴Multinational Organization Network Sponsoring Translational and Epidemiological Research
- 13 (MONSTER) Initiative, Salvador, Brazil
- ⁵Laboratory of Inflammation and Biomarkers, Gonçalo Moniz Institute, Oswaldo Cruz Foundation,
- 15 Salvador, Brazil
- 16 ⁶Curso de Medicina, Escola Bahiana de Medicina e Saúde Pública (EBMSP), Salvador, Brazil
- ⁷Curso de Medicina, Universidade Salvador (UNIFACS), Laureate Universities, Salvador, Brazil
 18
- 19 [#]Flávia M. Sant'Anna, Mariana Araújo-Pereira, Carolina A. S. Schmaltz and María B. Arriaga
- 20 equally contributed to the work.
- 21
- 22 *The senior authors Bruno B. Andrade and Valeria C Rolla equally contributed to the work.
- 23
- 24 * Correspondence: Bruno B. Andrade, MD, PhD. Laboratory of Inflammation and Biomarkers,
- 25 Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Rua Waldemar Falcao, 121, Candeal, Salvador,
- 26 Bahia 40296-710, Brazil. E-mail: Bruno.andrade@fiocruz.br.
- 27 Keywords: tuberculosis, tuberculosis treatment, adverse drug reaction, treatment outcomes,
- 28 loss to follow up.
- 29

30 ABSTRACT

31 Adverse drug reactions (ADR) challenge successful anti-tuberculosis treatment (ATT). The aim of this 32 study was to evaluate the impact of ATT-associated ADR and related factors on treatment outcomes. 33 A prospective cohort study of persons with tuberculosis at a referral center in Rio de Janeiro, Brazil, 34 from 2010 to 2016. ADRs, favorable (cure and treatment completion) and unfavorable (death, loss to 35 follow up and failure) outcomes were prospectively captured. The Kaplan-Meier curve was used to 36 estimate probability ADR-free time. A logistic regression model was performed to identify 37 independent associations with unfavorable outcomes. 550 patients were enrolled and 35.1% were 38 people living with HIV (PLHIV). ADR occurred in 78.6% of participants and was associated with 39 favorable outcomes. Smokers (OR:2.32;95%CI:1.34-3.99) and illicit drug users 40 (OR:2.02;95%CI:1.15-3.55) exhibited higher risk of unfavorable outcome. PLHIV more frequently 41 experienced grade 3/4-ADR, specially "liver and biliary system disorders". Lower CD4 counts were 42 associated with hepatotoxicity (p=0.03). Male sex, low schooling, smoking and illicit-drug use are 43 independent risk factors for unfavorable outcomes, as well alcohol abuse and previous ART in PLHIV. 44 ADR increases the odds of favorable outcomes, although it is more severe in PLHIV and related to a 45 higher risk of hepatotoxicity.

46 Introduction

47	Anti-tuberculosis treatment (ATT) has been available worldwide and can reach more than 90% of
48	effectiveness [1]. However, the challenges in achieving this goal persist as ATT can cause adverse drug
49	reactions (ADR) that lead to increased morbidity and compromise adherence eventually contributing
50	to treatment failure, relapse, or emergence of resistant strains [2,3].
51	The ATT recommended by World Health Organization (WHO) and implemented since 2009 in
52	the Brazilian guidelines is as a fixed-dose (FDC), single-tablet combination of four drugs (rifampicin,
53	isoniazid, pyrazinamide, and ethambutol) during the intensive phase of treatment followed by
54	rifampicin and isoniazid in FDC until the end of treatment [4]
55	Retrospective studies conducted in Brazil found an incidence of ADR between 23% to 83% [5-
56	7] and in a meta-analysis including other non-Brazilian studies, the incidence varied from 8.4% to
57	83.5% [8]. ADRs are multifactorial [9,10] and the major determinants are unadjusted prescribed doses
58	of medications, patient's age, nutritional status, alcohol consumption, liver and kidney function and
59	HIV-infection [11,12].
60	In people living with HIV (PLHIV), co-administration of antiretroviral therapy (ART) and ATT
61	increases the risk of drug interactions, immunopathological responses, and ADRs [13]. ADRs have
62	been associated with almost two-fold increased risk of unsuccessful treatment outcomes after 6 months
63	of ATT [14].
64	According to data from the Brazilian Ministry of Health, in the year of 2020, 8.5% of new
65	diagnoses of tuberculosis were in PLHIV [15]. ART during ATT is challenging because of drug-to-
66	drug interactions and increased risk of ADR. In Brazil there are few studies on ADR in PLHIV treating
67	TB, with no definitive conclusion. The aim of this study is to evaluate the impact of ADR due to ATT

- and factors associated with favorable and unfavorable outcomes. We hypothesize that ADR occurrence
- 69 could increase unfavorable outcome occurrences.

70 Methods

71 Ethics statement

The study was approved by the Institutional Review Board of the National Institute of Infectious Diseases Evandro Chagas (INI) (CAAE: 86215118.5.0000.5262). Written informed consent was obtained from all participants involved in the study and all clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.

76 Study design

We conducted a prospective cohort study with TB patients treated and followed up at the Clinical Research Laboratory on Mycobacteria (LAPCLIN-TB) of the National Institute of Infectious diseases Evandro Chagas (INI), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil, from January 2010 to December 2016. In LAPCLIN-TB a cohort study has been active since 2000, with data registered at a standardized visit template. The information is captured at each patient's visit. Raw data is shown in S1 File.

83 Inclusion and exclusion criteria

The inclusion criteria were 18 years old or more and pulmonary, extrapulmonary or disseminated TB. The exclusion criteria were death or loss to follow up (LTFU) within the first 15 days of ATT (early death or early LTFU avoiding data capture), rifampicin and isoniazid resistance (MDR) and lack of information on outcomes. Patients initially diagnosed with TB based on clinicalradiologic evaluation who were later diagnosed with another disease rather than tuberculosis were also excluded.

90 **TB diagnosis and follow up visits**

91 Tuberculosis diagnosis was clinical-radiological (based on symptoms and signs and chest X-ray 92 findings), in some cases confirmed by laboratory tests (acid fast smears and/or culture and/or 93 histopathological findings and/or Xpert-MTB/RIFTM). In cases without laboratory confirmation, a 94 positive therapeutic response to ATT was considered for TB diagnosis (clinical-radiological 95 improvement with ATT). Visits were scheduled at baseline (ATT initiation), 15, 30, 60, 90, 120, 150 96 and 180 days after ATT initiation. Sometimes treatment was prolonged, especially for disseminated or 97 extrapulmonary TB cases and due to a physician decision. In these cases, there were monthly visits 98 scheduled after the 180 days of ATT. Data were entered into an electronic medical record and 99 standardized information was collected using a predefined template in all visits.

100 During the baseline visit, information collected included demographic variables such as age, sex, race 101 (self-reported), marital status, schooling (illiterate, elementary school up to 12 years, and high 102 schooling above 12 years), social behavior (alcohol, tobacco, illicit drugs use/addiction), clinical 103 information such as clinical forms of tuberculosis (pulmonary, extrapulmonary or disseminated - 2 or 104 more non-contiguous sites), presence of comorbidities, and concomitant medications use. At baseline 105 visits laboratory tests were collected: hemogram, urea, creatinine, uric acid, alanine (ALT) and 106 aspartate (AST) transferases, albumin, alkaline phosphatase, gamma glutamyl transferase (GGT), chest 107 X-ray, hepatitis B, C and HIV serology. At subsequent visits, ADR were monitored with clinical 108 information and laboratory evaluation (hemogram and biochemistry including liver enzymes) in all 109 visits. For known PLHIV, CD4 count, and HIV viral load (VL) were added at baseline visits and at the 110 end of ATT.

111 Anti-TB treatment (ATT)

112	Since 2009, Brazilian guidelines incorporated WHO-recommendation of rifampicin 600 mg, isoniazid
113	300 mg, pyrazinamide 1600 mg and ethambutol 1100 mg in FDC for two months, followed by four
114	months of rifampicin 600 mg and isoniazid 300 mg in FDC, for both new and retreatment TB cases
115	until drug-susceptibility tests were available. Doses were adjusted for patients with less than 50kg [4].
116	HIV treatment
117	ART was prescribed for PLHIV, by each assistant physician, according to Brazilian guidelines for
118	Sexual Transmitted Diseases and AIDS [16]. The recommended ATT for PLHIV included a rifamycin
119	(rifampicin or rifabutin), which was chosen according to the ART regimen appropriate for each specific
120	patient. Rifabutin 150 mg/day was chosen when protease inhibitors were prescribed as part of ART
121	[11]. ART was introduced for naïve patients as soon as possible, which happened around the first month
122	of ATT in most cases.

123 Smoke habit

A current smoker was defined as someone who was smoking at the time of tuberculosis diagnosis and/or at the beginning of ATT or who stopped smoking due to tuberculosis symptoms but went back to smoke during ATT.

127 Illicit drug users

128 All patients who reported to be currently using drugs were considered illicit drug users.

129 Alcohol abusers

130 All patients answered the CAGE questionnaire [17] and those who answered yes to 2 or more questions

131 were considered as having significant alcohol addiction.

132 Adverse Drug Reaction (ADR)

133 ADR were defined according to signs and symptoms (clinical), laboratory tests abnormalities 134 (laboratory) or both (clinical and laboratory). ADRs were categorized according to WHO-ART classification [18]. The scale of intensity was based on the Division of AIDS table for grading the 135 136 severity of adult and pediatric ADR [19]: Grade 1: mild event, Grade 2: moderate event, Grade 3: 137 severe event, Grade 4: potentially life-threatening event, Grade 5: death. The causality of ADRs were 138 assessed using the Naranjo Scale, as improbable, possible, probable, and definitively related to the 139 medications [20]. Only probable, possible, and definitively related ADR were considered for the 140 analysis.

141 Outcomes

Outcomes were based on WHO criteria [21]. The success of treatment consisted of cure and treatment conclusion which were considered favorable outcomes. Unfavorable outcomes were grouped (composite outcome) and included treatment failure (remaining smear-positive after the 4th month of ATT), transfer to different treatment facilities (patients who were transferred out to other health unit), LTFU (interruption of treatment for two or more consecutive months) and death associated with tuberculosis (all cases were revised and the causality accessed).

148 Data analyses

Descriptive statistics was performed using the median values with interquartile ranges (IQR) as measures of central tendency and dispersion for continuous variables. Categorical variables were described using frequency (no.) and proportions (%). The Mann–Whitney U test (for two unmatched groups) was used to compare continuous variables and the Pearson chi-square test was used to compare categorical variables between study groups. The Kaplan-Meier curve was used to estimate ADR-free probabilities.

A logistic binary regression was performed with backward stepwise selection using variables with univariate p-value ≤0.2 to identify independent associations between characteristics of tuberculosis patients with the composite unfavorable treatment outcome. Results from regression were presented in terms of point estimates and 95% confidence intervals (CI). All analyses were pre-specified. Differences with p-values below 0.05 after adjustment for multiple comparisons (Holm-Bonferroni) were considered statistically significant.

161 The statistical analyses and data visualization were performed using rstatix (version 0.4.0), stats 162 (version 3.6.2), ggplot2 (version 3.3.2), survivor (version 3.2.7) and survminer (version 0.4.8) R 163 packages.

164 **Results**

From 2010 to 2016, 606 patients were enrolled in this study. Fifty-six patients with exclusion criteria were ruled out: 31 with MDR tuberculosis, 18 with other diagnoses during ATT (including nontuberculous mycobacteria), two due to early death, and one because of early LTFU. Two patients were removed from the dataset due to lack of information on the outcomes.

A total of 550 patients were included in this study. Only patients with ADR (total 426) were included in these analyses (Figure 1A). Table 1 shows a comparison of favorable and unfavorable outcomes regarding their sociodemographic and clinical characteristics. The median age was 38 years, 329 (59.8%) were male and 193 (35.1%) were PLHIV. Among patients with unfavorable outcomes: 84 were LTFU, 7 had a treatment failure and 7 died.

174 Figure 1. Study Design and probability of presenting adverse reactions during the antitubercular

175 treatment. (A) Study design. (B) Event free curve (Kaplan-Meier) of Tuberculosis patients

176 during antitubercular treatment. Mean time (in state, restricted max time = 365) in days of event

- 177 occurrence: 140.7. Abbreviation: ADR: adverse drug reaction; ATT: anti-TB treatment; CI:
- 178 confidence interval; TB: tuberculosis.
- 179
- 180 Table 1. Clinical, social demographics and comorbidities according to outcomes

	All (n=550)	Favorable	Unfavorable	р
		(n=452)	(n=98)	value
Male, n (%):	329 (59.8)	256 (56.6)	73 (74.5)	0.002
Age, median (IQR):	38 (29-49)	39 (29-50)	36 (28.2-46.8)	0.138
Race, n (%):				<0.001
White	281 (51.1)	250 (55.3)	31 (31.6)	
Black/Pardo	269 (48.9)	202 (44.7)	67 (68.4)	
Scholarity, n (%):				<0.001
Illiterate	21 (3.82)	16 (3.54)	5 (5.10)	
Elementary School	449 (81.6)	356 (78.8)	93 (94.9)	
High School	80 (14.5)	80 (17.7)	0 (0.00)	
Married, n (%):	279 (50.7)	239 (52.9)	40 (40.8)	0.040

Tobacco use, n (%):	191 (34.7)	134 (29.6)	57 (58.2)	<0.001
Alcohol abuse, n (%):	212 (38.5)	156 (34.5)	56 (57.1)	<0.001
Illicit drug use, n (%):	121 (22.0)	78 (17.3)	43 (43.9)	<0.001
Initial Weight, median (IQR):	58 (50.6- 67.5)	59.7 (50.7-9.6)	56.3 (50.1-64)	0.023
ADR occurrence, n (%):	431 (78.6)	372 (82.5)	59 (60.8)	<0.001
Type of TB, n (%):				0.023
РТВ	290 (52.7)	238 (52.7)	52 (53.1)	1
EPTB	170 (30.9)	148 (32.7)	22 (22.4)	0.060
Disseminated	90 (16.4)	66 (14.6)	24 (24.5)	0.025
Changed treatment, n (%):	64 (11.6)	49 (10.8)	15 (15.3)	0.282
Hepatitis B or C, n (%):	28 (5.09)	23 (5.09)	5 (5.10)	1

Diabetes mellitus, n (%):	50 (9.09)	46 (10.2)	4 (4.08)	0.087
Hypertension, n (%):	78 (14.2)	72 (15.9)	6 (6.12)	0.018
COPD, n (%):	10 (1.82)	9 (1.99)	1 (1.02)	1
HIV infection, n (%):	193 (35.1)	141 (31.2)	52 (53.1)	<0.001
ART naive, n (%)	74 (38.7)	62 (44.3)	12 (23.5)	0.015

181 Table Note:

182 Data are shown as median and interquartile (IQR) range or number and frequency (percentage). Data 183 were compared between the clinical groups using the Mann–Whitney U test (continuous variables) or 184 the Pearson's χ 2 tests (for data on frequency). Bold in p-value indicates p < 0.05.

Weight was measured in kilograms. Abbreviations: ADR: adverse drug reaction; HIV: Human
immunodeficiency virus; IQR: Interquartile Range; TB: tuberculosis;

187

188 All participants who died were PLHIV with clinical and/or laboratorial signs of advanced

- immunodeficiency. No deaths were related to ADR. We observed significant differences in race,
- 190 schooling, smoking habits, and alcohol consumption among cases with unfavorable outcomes when
- 191 compared to patients who experienced favorable outcomes. ADR occurred in 78.6% of participants,
- 192 35.1% of ADR were in PLHIV. Despite the high incidence, occurrence of ADR was higher in the group
- 193 of participants who experienced favorable ATT outcomes.

194 Our analysis of the type, severity, date of onset, relationship with the ATT and WHO-ART

195 classification according to outcomes are presented in Table 2. According to WHO-ART classification,

- 196 gastro-intestinal system disorders (23.9%) followed by "metabolic and nutritional disorders" (22.4%),
- 197 were the most prevalent ADR related to unfavorable outcomes. The probability of ADR was higher
- 198 until 140 days of ATT (Figure 1B). In the logistic regression model, smoking habit, illicit drugs use,
- and HIV-infection were associated with unfavorable outcomes (Figure 2).

200 Table 2. ADR characteristics according to ATT outcome

	All (n=695)	Favorable (n=628)	Unfavorable (n=67)	p value
Type of event, n (%):				0.95
Clinical + Laboratory	87 (12.5)	78 (12.4)	9 (13.4)	
Laboratory	228 (32.8)	207 (33.0)	21 (31.3)	
Clinical	380 (54.7)	343 (54.6)	37 (55.2)	
Adverse reactions duration (days), median (IQR):	77.0 (39.0- 142)	81.5 (43.0-147)	44.0 (25.0-85.0)	<0.001
Severity of ADR, n (%):				0.128
Grade 1	264 (38.0)	246 (39.2)	18 (26.9)	

Grade 2	352 (50.6)	314 (50.0)	38 (56.7)	
Grade 3	67 (9.64)	57 (9.08)	10 (14.9)	
Grade 4	12 (1.73)	11 (1.75)	1 (1.49)	
Onset of ADR, n (%):				0.38
before 2nd month (early)	592 (85.2)	532 (84.7)	60 (89.6)	
after month 2 (late)	103 (14.8)	96 (15.3)	7 (10.4)	
Relation of ADR with ATT, n (%):				0.601
Related	14 (2.01)	14 (2.23)	0 (0.00)	
Probable	171 (24.6)	153 (24.4)	18 (26.9)	
Possible	510 (73.4)	461 (73.4)	49 (73.1)	
WHO ART classification, n (%):				0.207

Central and peripheral nervous system disorders	45 (6.47)	43 (6.85)	2 (2.99)	
Gastro-intestinal system disorder	151 (21.7)	135 (21.5)	16 (23.9)	
Liver and biliary system disorders	54 (7.77)	44 (7.01)	10 (14.9)	
Metabolic and nutritional disorders	171 (24.6)	156 (24.8)	15 (22.4)	
Musculo-skeletal disorders	63 (9.06)	56 (8.92)	7 (10.4)	
Other	46 (6.62)	45 (7.17)	1 (1.49)	
Skin and appendages disorders	125 (18.0)	113 (18.0)	12 (17.9)	

201 Table Note:

202 Data are shown as median and interquartile (IQR) range or number and frequency (percentage). Data

203 were compared between the clinical groups using the Mann–Whitney U test (continuous variables) or

204 the Pearson's χ 2 tests (for data on frequency). Bold in p-value indicates p < 0.05.

Figure 2. Association between clinical characteristics and tuberculosis treatment outcomes among tuberculosis patients. The logistic binary regression model (backward stepwise regression) was performed to evaluate the independent associations between clinical characteristics, including adverse drug reaction occurrence, of tuberculosis patients and variables with p-value <0.2 results in the univariate analyses (Table 1) and unfavorable treatment outcome. Abbreviation: ADR: adverse drug reaction; CI: confidence interval; TB: tuberculosis.

213 We compared the clinical characteristics and ADR presentation of patients according to HIV status and 214 noted that there were significant differences between the groups (Table 3). Self-reported race, marital 215 status, smoking habits, alcohol abuse, illicit drug use in the PLHIV group were associated with 216 unfavorable outcomes. ADR occurred in 78.6% of total participants and 72,8% of them were in the 217 PLHIV. Although diagnosis of viral hepatitis serology was included in our model, it was not associated 218 with unfavorable outcomes, but the number of positive cases was small and we did not test viral load 219 to confirm active hepatitis. The main finding of this investigation was that PLHIV experienced more 220 severe forms of ADR than HIV-unexposed participants, especially liver and biliary system disorders 221 (Table 4).

222 Table 3. Sociodemographics and clinical characteristics of patients according to HIV status

	All (n=425)	HIV	non-HIV	p value
		(n=141)	(n=284)	
Male, n (%):	258 (60.6)	97 (68.8)	161 (56.5)	0.019

Age, median (IQR):	39.0 (29.0-50.0)	37.0 (31.0- 47.0)	40.0 (28.0- 53.0)	0.244
White (race), n (%):	230 (54.0)	52 (36.9)	178 (62.5)	<0.001
Married, n (%):	229 (53.8)	57 (40.4)	172 (60.4)	<0.001
Tobacco use, n (%):	144 (33.8)	64 (45.4)	80 (28.1)	0.001
Alcohol abuse, n (%):	160 (37.6)	70 (49.6)	90 (31.6)	<0.001
Illicit drug use, n (%):	88 (20.7)	44 (31.2)	44 (15.4)	<0.001
Type of TB, n (%):				<0.001
РТВ	222 (52.1)	65 (46.1)	157 (55.1)	
EPTB	135 (31.7)	19 (13.5)	116 (40.7)	
Disseminated	69 (16.2)	57 (40.4)	12 (4.21)	
Initial Weight, median (IQR):	59.0 (51.0-68.0)	59.6 (50.7- 68.0)	57.1 (53.8- 64.0)	0.836

Hepatitis B or C, n	21 (4.93)	11 (7.80)	10 (3.51)	0.091
(%):				
Diabetes mellitus, n (%):	41 (9.62)	11 (7.80)	30 (10.5)	0.47
Hypertension, n (%):	70 (16.4)	12 (8.51)	58 (20.4)	0.003
COPD, n (%):	8 (1.88)	1 (0.71)	7 (2.46)	0.28

Table Note: 223

Data are shown as median and interquartile (IQR) range or number and frequency (percentage). Data were compared between the clinical groups using the Mann–Whitney U test (continuous variables) or the Pearson's χ 2 tests (for data on frequency). Bold in p-value indicates p < 0.05.

Weight was measured in kilograms. Abbreviations: COPD: Chronic obstructive pulmonary disease;
 ART: Antiretroviral Therapy; HIV: Human immunodeficiency virus; IQR: Interquartile Range; TB:
 tuberculosis.

230

231 Table 4. ADR characteristics according to intensity of ADR in PLHIV

		ADR 1/2	ADR 3/4	
	All (n=273)	(n=223)	(n=50)	p value
Type of event, n (%):				<0.001
Laboratory	96 (35.2)	73 (32.7)	23 (46.0)	
Clinical	122 (44.7)	115 (51.6)	7 (14.0)	
Clinical +				
Laboratory	55 (20.1)	35 (15.7)	20 (40.0)	

Onset of ADR,	21.0 (12.00-	21.0 (11.0-	20.0 (14.00-	
median (IQR):	55.0)	60.0)	35.0)	<0.001
Adverse reactions				
duration (days),	77.0 (35.0-	75.0 (36.0-	83.0 (31.0-	
median (IQR):	136)	126)	153)	0.731
Severity of ADR, n				
(%):				0.308
Grade 1	90 (33.0)	90 (40.4)	0 (0.00)	
Grade 2	133 (48.7)	133 (59.6)	0 (0.00)	
Grade 3	43 (15.8)	0 (0.00)	43 (86.0)	
Grade 4	7 (2.56)	0 (0.00)	7 (14.0)	
Relation ADR with				
ATT, n (%):				0.043
Probable	64 (23.4)	46 (20.6)	18 (36.0)	
Possible	201 (73.6)	171 (76.7)	30 (60.0)	
Related	8 (2.93)	6 (2.69)	2 (4.00)	
Onset of ADR, n (%):				0.019
before 2nd month				
(early)	215 (78.8)	169 (75.8)	46 (92.0)	
after month 2 (late)	58 (21.2)	54 (24.2)	4 (8.00)	

WHO ART				
classification, n (%):				
Central and				
peripheral nervous				
system disorders	13 (4.76)	12 (5.38)	1 (2.00)	
Gastro-intestinal				
system disorder	42 (15.4)	42 (18.8)	0 (0.00)	
Liver and biliary				
system disorders	41 (15.0)	22 (9.87)	19 (38.0)	
Metabolic and				
nutritional disorders	52 (19.0)	47 (21.1)	5 (10.0)	
Musaulo skolotal	× ,	×)	`` ,	
	25(12.0)	2((11.7))	0 (10 0)	
disorders	35 (12.8)	26 (11.7)	9 (18.0)	
Other	15 (5.49)	13 (5.83)	2 (4.00)	
Skin and				
appendages disorders	45 (16.5)	42 (18.8)	3 (6.00)	
White cell and RES				
and platelet disorders	30 (11.0)	19 (8.52)	11 (22.0)	
WHO ART				
dichotomized, n (%):				<0.001
Liver and biliarv				
system disorders	41 (15 0)	22 (9 87)	19 (38 0)	

Others 232 (85.0) 201 (90.1) 31 (62.0)

232 Table Note:

Data are shown as median and interquartile (IQR) range or number and frequency (percentage). Data were compared between the clinical groups using the Mann–Whitney U test (continuous variables) or the Pearson's χ 2 tests (for data on frequency). Bold in p-value indicates p < 0.05. Abbreviations: ADR: adverse drug reaction; HIV: Human immunodeficiency virus; IQR: Interquartile Range; TB: tuberculosis;

239	According to clinical data, it was observed that among PLHIV, median CD4 count was 166 cell/ μ l and
240	those with ADR grade 3 and 4 had lower CD4 count compared to those with ADR grade 1 and 2 and
241	most of those with ADR grade 3/4 displayed CD4 count below 100/uL (Table 5). The characteristics
242	of ADR differed between cases of grade 1/2 compared to those graded 3/4 in terms of type, time of
243	onset, relationship with treatment, and affected system. The most affected system in patients with grade
244	3/4 ADR was the liver and biliary system (Table 5). Considering all PLHIV, 53.1% experienced
245	unfavorable outcomes (p<0.001). Among them, 183 (33.3%) were ART-experienced while 38.7%
246	ART naïve. In the group of ART experienced patients, 48 (49%) experienced unfavorable outcomes
247	(p<0.001).

248	Table 5.	Clinical	and lab	oratory	charac	teristics	according	to inte	nsity o	f ADR	in PL	HIV
-												

	All (n=140)	1/2 (n=114)	3/4 (n=26)	p value
Type of TB, n (%):				<0.001
РТВ	65 (46.1)	55 (48.2)	10 (38.5)	
EPTB	19 (13.5)	16 (14.0)	3 (11.5)	

Disseminated	57 (40.4)	43 (37.7)	13 (50.0)	
HIV Viral Load, median (IQR):	4.53 (3.26-5.33)	4.44 (3.21- 5.40)	4.86 (3.55- 5.21)	0.871
CD4 (cells/uL), median (IQR):	166 (43.0-353)	176 (52.8- 360)	110 (26.8- 180)	0.065
CD4 levels, n (%):				0.033
<100	56 (40.0)	43 (37.8)	13 (50.0)	
100-200	30 (21.4)	21 (18.4)	9 (34.6)	
>200	54 (38.6)	50 (43.9)	4 (15.4)	
Initial Weight, median (IQR):	59.0 (51.0-68.0)	59.6 (50.7- 68.0)	57.1 (53.8- 64.0)	0.836
Hepatitis B or C, n (%):	11 (7.86)	11 (9.65)	0 (0.0)	0.091
Diabetes mellitus, n (%):	10 (7.14)	7 (6.1)	3 (11.5)	0.47
Hypertension, n (%):	10 (7.14)	8 (7.01)	2 (7.7)	1.000

COPD, n (%):	1 (0.71)	1 (0.88)	0 (0.0)	1.000

249 Table Note:

- 250 Data are shown as median and interquartile (IQR) range or number and frequency (percentage). Data
- were compared between the clinical groups using the Mann–Whitney U test (continuous variables) or the Pearson's x/2 tests (for data on frequency). Bold in p value indicates p < 0.05
- 252 the Pearson's χ 2 tests (for data on frequency). Bold in p-value indicates p < 0.05.
- 253 Weight was measured in kilograms. Abbreviations: COPD: Chronic obstructive pulmonary disease;
- ART: Antiretroviral Therapy; HIV: Human immunodeficiency virus; IQR: Interquartile Range; TB:
- 255 tuberculosis.
- 256

257 Discussion

The impact of unsuccessful ATT can directly impair the strategies for TB control [22,23]. The main findings of our study were: ADR was not associated with unfavorable outcomes and PLHIV had higher ADR intensity than HIV-unexposed study participants, which were mainly liver and biliary system disorders, especially those with lower CD4 counts.

As expected, most patients who were lost to follow up had licit or illicit drug addiction. These findings are of great importance for planning strategies to decrease harm but increase early ART, even with the risk of drug to drug interaction. As there was a considerable LTFU, representing the predominant unfavorable outcome, it is urgent to create policies to increase treatment adherence.

In our data male sex was found to be significantly associated with unfavorable outcomes. A possible explanation is that men were less likely to regularly follow treatment when compared with women in our setting [15]. In our study, low schooling, smoke habit and illicit drug use were associated with unfavorable outcomes. However, among PLHIV, alcohol abuse was the only independent factor associated with unfavorable outcomes. Other studies in the literature have shown the same correlation between alcohol abuse [2,24,25] and in the general population, smoke habit was associated with unfavorable outcomes as well as in our study [26].

ADRs were not associated with unfavorable outcomes, contrary to our primary expectations. Probably, patients who experienced ADR were better managed and/or more closely monitored, which contributed to feeling well cared for and having a good adherence to therapy. In contrast, a previous prospective study in Rwanda with TB patients, with or without HIV-infection, has shown that ADRs were associated with an almost two-fold increased risk of LTFU [2].

Another correlation observed in our study was that high schooling participants did not present anyunfavorable outcome, which was not a surprise since they probably have a better understanding about

the importance of treatment adherence for TB cure. Definitive treatment interruption before cure can
lead to recurrence, development of drug resistance, increased costs and a worse epidemiologic situation
[27].

283 We also explored the liver and biliary system disorders in advanced HIV patients and a high incidence 284 of hepatotoxicity was associated with low CD4 count, mainly in those with less than 100 cells//uL. 285 This important finding should help the management of TB in patients with HIV, since more attention 286 will be directed to this type of ADR in this population. Most ART naïve patients are diagnosed with 287 HIV due to TB, as HIV serology is done in all patients with TB diagnosis [11]. These are, in general, 288 the most severe cases and hospitalization is sometimes necessary not only for TB diagnosis but also to 289 manage severe and serious ADR after ATT introduction. The early ART start in these cases is of special 290 interest due to the added risk of hepatotoxicity. Sometimes, when ADR occurs, it is necessary to stop 291 all drugs and reintroduce one by one to identify the causality. Many studies also have found that PLHIV 292 using concomitant ART and ATT had a higher frequency of ADR and low adherence to treatment [27-293 29].

In our study we found 26% of PLHIV developing unfavorable outcomes. ART-naïve patients presented a higher incidence of ADR in comparison with ART-experienced PLHIV, although the latter group more frequently developed unfavorable outcomes, especially LTFU. Most of these patients were already cared for at the study referral center or other health clinics and had TB due to low adherence to ART. These patients are different from ART-naïve patients that had a recent TB diagnosis and were tested for HIV for the first time.

300 In our routine care, ART commencement occurs as soon as possible in the first month of TB treatment 301 for those with low CD4 counts, as well as cotrimoxazole prophylaxis, since this approach has already 302 been proved to reduce mortality [30]. Although all those challenges reported here, our TB lethality was

303 relatively low in PLHIV which shows that the strategy of early ART start works and ADR can be 304 successfully managed.

In conclusion male sex, low schooling, smoke habit, and illicit drug use were all independently associated with unfavorable outcomes during ATT. In PLHIV, alcohol abuse and previous ART use were factors associated with unfavorable outcomes. ADR was more frequent in the beginning of TB treatment and was not associated with unfavorable outcomes.

In our study, clinical center patients were attended by different physicians who in general conduct the whole treatment and have laboratory exams available to help ADRs detection and management. Also, medical care was available at the hospital every day, 24 hours a day, which helps ADR management any time they occur. We had some limitations: directly observed treatment (DOT) was not performed in our site due to our characteristics of being a tertiary hospital and far from most patients' houses. Viral hepatitis were screened with serology and no viral load was performed, the low proportion of viral hepatitis in our study limited the analyses in this group.

The identification of factors associated with unfavorable outcomes could allow health care to appropriately risk-stratify patients for closer management and improve outcomes. In addition, investments in programs destined to reduce tobacco, alcohol and drug addiction are also necessary to improve TB treatment adherence and decrease LTFU. On the other hand, an investment in education is necessary by the government to make patients better understand the disease and the importance of treatment completion.

322 Conflict of interest

323 The authors declare that the research was conducted in the absence of any commercial or financial324 relationships that could be construed as a potential conflict of interest.

325 Author Contributions

326 FS, CS and VR contributed to conception and design of the study. FS collected the data and organized 327 the initial database. MA-P and MA performed the statistical analysis and data visualization. VR and 328 BA supervised the project execution. All authors contributed to manuscript writing, revision, read, and 329 approved the submitted version.

330 Funding

331 This work was supported by Brazilian Program of STD-AIDS and Viral Hepatitis, in partnership with 332 the UNODC and the Clinical Research Laboratory on Mycobacteria of INI, FIOCRUZ, edital 333 modalidade pesquisas nº 01/2013. The study was partially supported by the Intramural Research 334 Program of the Fundação Oswaldo Cruz. B.B.A and V.C.R. are senior scientists from the Conselho 335 Nacional de Desenvolvimento Científico e Tecnológico (CNPq). M.B.A. received a scholarship from Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB). M.A.P. received a research fellowship 336 337 from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, finance code: 001). 338 The funders had no role in study design, data collection and analysis, decision to publish, or preparation 339 of the manuscript.

340 Acknowledgments

- 341 The authors thank the study participants.
- 342
- 343 Supplementary material
- 344 S1 File. Raw data.

345

347 **REFERENCES**

- World Health Organization. Global tuberculosis report 2021. Geneva; 2021. Available: https://www.who.int/publications-detail-redirect/9789240037021
- Castro ATE, Mendes M, Freitas S, Roxo PC. Incidence and risk factors of major toxicity
 associated to first-line antituberculosis drugs for latent and active tuberculosis during a period of
 10 years. Rev Port Pneumol (2006). 2015;21: 144–150. doi:10.1016/j.rppnen.2014.08.004
- Lorent N, Sebatunzi O, Mukeshimana G, Ende JV den, Clerinx J. Incidence and Risk Factors of
 Serious Adverse Events during Antituberculous Treatment in Rwanda: A Prospective Cohort
 Study. PLOS ONE. 2011;6: e19566. doi:10.1371/journal.pone.0019566
- Brasil. Nota técnica sobre as mudanças no tratamento da tuberculose no Brasil para adultos e
 adolescentes. Ministério da Saúde; 2010.
- Arriaga MB, Torres NMC, Araujo NCN, Caldas SCC, Andrade BB, Netto EM. Impact of the
 change in the antitubercular regimen from three to four drugs on cure and frequency of adverse
 reactions in tuberculosis patients from Brazil: A retrospective cohort study. PLoS One. 2019;14:
 e0227101. doi:10.1371/journal.pone.0227101
- Ferreira ACG, Silva Júnior JLR da, Conde MB, Rabahi MF. Desfechos clínicos do tratamento de tuberculose utilizando o esquema básico recomendado pelo Ministério da Saúde do Brasil com comprimidos em dose fixa combinada na região metropolitana de Goiânia. J bras pneumol. 2013;39: 76–83. doi:10.1590/S1806-37132013000100011
- Maciel ELN, Guidoni LM, Favero JL, Hadad DJ, Molino LP, Jonhson JL, et al. [Adverse
 effects of the new tuberculosis treatment regimen recommended by the Brazilian Ministry of
 Health]. J Bras Pneumol. 2010;36: 232–238. doi:10.1590/s1806-37132010000200012
- Singh A, Prasad R, Balasubramanian V, Gupta N, Gupta P. Prevalence of adverse drug reaction
 with first-line drugs among patients treated for pulmonary tuberculosis. Clinical Epidemiology
 and Global Health. 2015;3: S80–S90. doi:10.1016/j.cegh.2015.10.005
- Prasad R, Singh A, Gupta N. Adverse drug reactions in tuberculosis and management. Indian J Tuberc. 2019;66: 520–532. doi:10.1016/j.ijtb.2019.11.005
- Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug
 Saf. 2006;5: 231–249. doi:10.1517/14740338.5.2.231
- 11. BRASIL. Manual de Recomendações para o Controle da Tuberculose no Brasil. 2019; 366.
- 377 12. Treatment of Tuberculosis. N Engl J Med. 2015;373: 2149–2160.
 378 doi:doi:10.1056/NEJMra1413919
- Masuka JT, Chipangura P, Nyambayo PP, Stergachis A, Khoza S. A Comparison of Adverse
 Drug Reaction Profiles in Patients on Antiretroviral and Antitubercular Treatment in Zimbabwe.
 Clin Drug Investig. 2018;38: 9–17. doi:10.1007/s40261-017-0579-z

- Incidence and risk factors of serious adverse events during antituberculous treatment in
 Rwanda: a prospective cohort study PubMed. [cited 15 Mar 2022]. Available:
 https://pubmed.ncbi.nlm.nih.gov/21611117/
- Boletim Tuberculose 2021 | Departamento de Doenças de Condições Crônicas e Infecções
 Sexualmente Transmissíveis. [cited 15 Mar 2022]. Available: http://www.aids.gov.br/pt br/pub/2021/boletim-tuberculose-2021
- BRASIL. Guia de Tratamento: Recomendações para Terapia Anti-retroviral em Adultos e
 Adolescentes Infectados pelo HIV:2008. Ministério da Saúde; 2008.
- Williams N. The CAGE questionnaire. Occup Med (Lond). 2014;64: 473–474.
 doi:10.1093/occmed/kqu058
- 392 18. Centre UM. Uppsala Monitoring Centre. [cited 15 Mar 2022]. Available: https://who-umc.org/
- Bivision of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse
 Events. : 35.
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating
 the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30: 239–245.
 doi:10.1038/clpt.1981.154
- World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment,
 service delivery and monitoring: recommendations for a public health approach. 2021.
 Available: https://www.who.int/publications-detail-redirect/9789240031593
- 401 22. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens PubMed.
 402 [cited 15 Mar 2022]. Available: https://pubmed.ncbi.nlm.nih.gov/17705952/
- Xia YY, Hu DY, Liu FY, Wang XM, Yuan YL, Tu DH, et al. Design of the Anti-tuberculosis
 Drugs induced Adverse Reactions in China National Tuberculosis Prevention and Control
 Scheme Study (ADACS). BMC Public Health. 2010;10: 267. doi:10.1186/1471-2458-10-267
- Przybylski G, Dąbrowska A, Trzcińska H. Alcoholism and other socio-demographic risk factors
 for adverse TB-drug reactions and unsuccessful tuberculosis treatment data from ten years'
 observation at the Regional Centre of Pulmonology, Bydgoszcz, Poland. Med Sci Monit.
 2014;20: 444–453. doi:10.12659/MSM.890012
- Zhang T, Du J, Yin X, Xue F, Liu Y, Li R, et al. Adverse Events in Treating Smear-Positive
 Tuberculosis Patients in China. Int J Environ Res Public Health. 2015;13: E86.
 doi:10.3390/ijerph13010086
- Liew SM, Khoo EM, Ho BK, Lee YK, Mimi O, Fazlina MY, et al. Tuberculosis in Malaysia:
 predictors of treatment outcomes in a national registry. Int J Tuberc Lung Dis. 2015;19: 764–
 771. doi:10.5588/ijtld.14.0767
- Lv X, Tang S, Xia Y, Wang X, Yuan Y, Hu D, et al. Adverse reactions due to directly observed
 treatment strategy therapy in Chinese tuberculosis patients: a prospective study. PLoS One.
 2013;8: e65037. doi:10.1371/journal.pone.0065037

- 419 28. Marks DJB, Dheda K, Dawson R, Ainslie G, Miller RF. Adverse events to antituberculosis
 420 therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS. 2009;20: 339–345.
 421 doi:10.1258/ijsa.2008.008361
- 422 29. Breen RAM, Swaden L, Ballinger J, Lipman MCI. Tuberculosis and HIV co-infection: a
 423 practical therapeutic approach. Drugs. 2006;66: 2299–2308. doi:10.2165/00003495-200666180424 00003
- 30. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of
 Antiretroviral Therapy for HIV-1 Infection and Tuberculosis. N Engl J Med. 2011;365: 1482–
 1491. doi:10.1056/NEJMoa1013607

Prospective cohort study

606 TB patients treated at the National Institute of Infectious Diseases Evandro Chagas – Rio de Janeiro, Brazil



- Early death: 2
- Early abandnment: 1
- Changed diagnosis: 8
 Unknown outcome: 2

550 TB patients enrolled, signed consent and included in the study



Figure 1



Figure 2